Human Longevity and Insilico Launch AI Longevity Platform
SOUTH SAN FRANCISCO, California, May 27, 2026 Human Longevity, Inc. (HLI) has announced the creation of Human Life Foundation...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, California, May 27, 2026 Human Longevity, Inc. (HLI) has announced the creation of Human Life Foundation...
Cambridge, Massachusetts, USA, April 21, 2026 In a transformative step for AI-driven biotechnology and longevity science, Insilico Medicine has...
